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3German Center for Infection Research (DZIF), GermanyBackground & Aims: The human liver bile acid transporter Na+/
taurocholate cotransporting polypeptide (NTCP) has recently
been identiﬁed as liver-speciﬁc receptor for infection of hepatitis
B virus (HBV), which attaches via the myristoylated preS1 (myr-
preS1) peptide domain of its large surface protein to NTCP. Since
binding of the myr-preS1 peptide to NTCP is an initiating step of
HBV infection, we investigated if this process interferes with the
physiological bile acid transport function of NTCP.
Methods: HBV infection, myr-preS1 peptide binding, and bile
acid transport assays were performed with primary Tupaia
belangeri (PTH) and human (PHH) hepatocytes as well as NTCP-
transfected human hepatoma HepG2 cells allowing regulatedJournal of Hepatology 20
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Abbreviations: HBV, hepatitis B virus; WMHBV, woolly monkey hepatitis B virus;
WHV, woodchuck hepatitis B virus; myr-preS1, N-terminal myristoylated and
C-terminal strep-tagged preS1-lipopeptide from N-terminal amino acids 2-48 of
the large surface protein of the respective HBV; myr-preS1-AX594, N-terminal
myristoylated and C-terminal ﬂuorescently labelled with dye Alexa594 from
N-terminal amino acids 2-48 of the large surface protein of HBV; NTCP, Na+/
taurocholate cotransporting polypeptide; SLC, solute carrier; ASBT, apical
sodium-dependent bile acid transporter; SOAT, sodium-dependent organic anion
transporter; DHEAS, dehydroepiandrosterone sulfate; TMD, transmembrane do-
main; TBHBV, tent-making bat HBV; PTH, primary Tupaia belangeri hepatocytes;
PHH, primary human hepatocytes; HDV, hepatitis D virus; tNtcp, Tupaia belangeri
Ntcp; HEK293, human embryonic kidney 293 cells; HepG2, human hepatocellular
liver carcinoma cell line; DMEM, Dulbecco’s modiﬁed Eagle medium; FCS, fetal
calf serum; TC, taurocholic acid; HGM, hepatocyte growth medium; HbeAg,
hepatitis B e antigen; HbsAg, Hepatitis B surface antigen; GE, genome equiva-
lents; ELISA, enzyme linked immunosorbent assay; PFA, paraformaldehyde; PBS,
phosphate buffered saline; RT, room temperature; HbcAg, Hepatitis B core
antigen; BSA, bovine serum albumin; PCC, Pearson’s correlation coefﬁcient; GC,
glycocholic acid; UDC, ursodeoxycholic acid; TUDC, tauroursodeoxycholic acid;
GUDC, glycoursodeoxycholic acid; DHC, dehydrocholic acid; EZ, ezetimibe; TLC,
taurolithocholic acid; OATP, organic anion transporting polypeptide; PBC,
primary biliary cirrhosis; pp, post preparation; DOX, Doxycycline.NTCP expression, in the presence of various bile acids, ezetimibe,
and myr-preS1 peptides.
Results: The myr-preS1 peptide of HBV inhibited bile acid
transport in PTH and PHH as well as in NTCP-expressing
HEK293 and HepG2 cells. Inversely, HBV infection of PTH, PHH,
and NTCP-transfected HepG2 cells was inhibited in a concentra-
tion-dependent manner by taurine and glycine conjugates of cho-
lic acid and ursodeoxycholic acid as well as by ezetimibe. In
NTCP-HepG2 cells and PTH, NTCP expression, NTCP transport
function, myr-preS1 peptide binding, and HBV infection followed
comparable kinetics.
Conclusions:Myr-preS1 virus binding to NTCP, necessary for
productive HBV infection, interferes with the physiological bile
acid transport function of NTCP. Therefore, HBV infection via
NTCP may be lockable by NTCP substrates and NTCP-inhibiting
drugs. This opens a completely new way for an efﬁcient manage-
ment of HBV infection by the use of NTCP-directed drugs.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
More than 2 billion people have been infected with hepatitis B
virus (HBV), giving rise to 240 million chronic HBV carriers and
620,000 HBV-associated deaths annually [1]. While there is an
effective prophylactic vaccine, HBV therapy with interferon is
often ineffective and inhibitors of HBV reverse transcription
usually have to be given life-long. To maintain the high efﬁcacy
of the HBV vaccine and to improve the therapy options of hepa-
titis B, a better understanding of the early steps of infection
would be useful.
HBV is a member of the still growing family of hepadnaviridae.
Mammalian hepadnaviruses form the genus orthohepadnavirus
also include woolly monkey hepatitis B virus (WMHBV), wood-
chuck hepatitis B virus (WHV), and three newly discovered bat
hepatitis B virus species with a zoonotic potential [2]. The myri-
stoylated preS1-lipopeptide comprising the N-terminal amino
acids 2-48 (myr-preS1) of the large HBV surface protein is essen-
tial for the species- and differentiation-dependent infection of14 vol. 61 j 867–875
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human hepatocytes, but the identity of the high-afﬁnity HBV
receptor(s) has been elusive for long [3]. Recently, the Na+/tauro-
cholate cotransporting polypeptide (NTCP in human, Ntcp in
other species) could be identiﬁed as the functional species-
speciﬁc HBV receptor [4]. NTCP/Ntcp belongs to the solute carrier
family 10 (SLC10), also referred to as the ‘‘family of sodium-
dependent bile acid transporters’’ which comprises seven mem-
bers (SLC10A1-SLC10A7) [5]. NTCP (SLC10A1) is speciﬁcally
expressed at the basolateral membrane of hepatocytes and is
essentially involved in the reuptake of bile acids from the portal
blood into hepatocytes for their resecretion into bile [6]. From the
gut, bile acids are efﬁciently recovered by the apical sodium-
dependent bile acid transporter ASBT (SLC10A2), which is highly
expressed at the apical brush-border membrane of enterocytes
in the terminal ileum [7]. A further transporter closely related
to NTCP and ASBT is represented by the sodium-dependent
organic anion transporter SOAT (SLC10A6), which is mainly
expressed in reproductive organs and has a dominant transport
function for sulfated steroids, such as dehydroepiandrosterone
sulfate (DHEAS) [8]. NTCP, ASBT, and SOAT share similar gene
structure, high sequence similarity of >60%, and a common nine
transmembrane domain (TMD) topology with Nexo/Ccyt orienta-
tion of the N- and C-terminal domains based on recent crystal
structure analysis of a bacterial ASBT homologue [7].
The initial attachment of HBV to hepatocytes occurs at the
basolateral membrane and is mediated mainly by low-afﬁnity
binding between the antigenic loop of the small hepatitis B surface
protein domain and heparan-sulfate proteoglycanes [9,10]. There-
after, high-afﬁnity interaction between HBV myr-preS1 and NTCP
is regarded as initial step for HBV uptake and infection. Amino
acids 157-165 of NTCP located at the N-terminal end of TMD5 as
well as amino acids 84-87 in the extracellular loop upstream of
TMD3 were shown to be involved in this interaction [4,11–13].
The interaction betweenNTCP andmyr-preS1 determines the host
range and liver tropism of primate HBVs and amazingly also those
of the related TBHBV species of the tent-making bats. Primary
hepatocytes of the asian treeshrew Tupaia belangeri (PTH) also
support infection with the primate viruses HBV and WMHBV
[14,15] and with hepatitis D virus (HDV) pseudotyped with
surface proteins of TBHBV [2]. This susceptibility seems to be
caused by a conserved domain of the human NTCP and Tupaia
belangeri Ntcp (tNtcp) at the site of virus binding [4]. However,
PTH are unable to support infection of rodent HBV, e.g. WHV [15].
The well-established HBV susceptible models of PTH and PHH
as well as human NTCP-transfected HEK293 and HepG2 cell cul-
tures allowed us to study if the physiological bile acid transport
function of NTCP may interfere with myr-preS1 peptide binding
to NTCP and HBV infection of NTCP/tNtcp expressing cells. Inter-
estingly, we found both processes to be highly connected and
thereby provide evidence that HBV infection via NTCP may be
lockable by NTCP substrates and NTCP-inhibiting drugs.Materials and methods
Transporter cDNA constructs, stably transfected cell lines, and transport assays
Transporter cDNA constructs were generated containing the full open reading
frames of human NTCP, ASBT, and SOAT in different expression vectors (for more
details see Supplementary materials and methods), allowing expression of the
respective FLAG-tagged or GFP-tagged fusion proteins after transfection in human
embryonic kidney HEK293 or HepG2 hepatoma cell lines. Flp-In T-REx-293 cells868 Journal of Hepatology 201(Invitrogen) were used to generate stably transfected tetracycline inducible
NTCP-HEK293, ASBT-HEK293, and SOAT-HEK293 cell lines as described in detail
in the Supplementary materials and methods. ASBT/NTCP and SOAT/NTCP chime-
ric constructs were generated by replacing amino acids 91-94 and 163-171 in
ABST and SOAT by the corresponding amino acids 84-87 and 157-165 of NTCP
using site-directed mutagenesis.
Human HepG2 hepatoma cells were cultivated in Dulbecco’s modiﬁed Eagle
medium (DMEM) (PAA, Cölbe, Germany) supplemented with 5% fetal calf serum
(FCS) (PAN, Aidenbach, Germany) and penicillin/streptomycin (PAA) at 37 C, 5%
CO2 and 95% humidity. Generation of the stably transfected NTCP-HepG2 cell line,
which is variably inducible by doxycycline (DOX) treatment is described in detail
in the Supplementary materials and methods.
All stably transfected cell lines as well as PTH and PHH were used for trans-
port assays with [3H]taurocholic acid ([3H]TC) or [3H]dehydroepiandrosterone
sulfate ([3H]DHEAS) (Perkin Elmer, Rodgau, Germany) in Na+-containing or Na+-
free transport buffers as described [8]. Transport inhibition experiments were
started by incubation with the respective inhibitory compounds or myr-preS1
peptides dissolved in transport buffer for 30 min at 37 C, before the transport
assay was started by adding [3H]TC or [3H]DHEAS to the cells. Uptake was termi-
nated after 10 min and the cell-associated radioactivity was determined by liquid
scintillation counting.
Primary tupaia and human hepatocytes
Primary hepatocytes from Tupaia belangeri (PTH) were isolated by a modiﬁed two
step collagenase method and cultivated in modiﬁed hepatocyte growth medium
(HGM) as described [13]. PTH were used for infection and transport experiments
at day three after preparation unless otherwise noted. PHHwere obtained fromPri-
macyt Cell Culture Technology GmbH (Schwerin, Germany). More detailed speci-
ﬁcations about the PHH are provided in the Supplementarymaterials andmethods.
Isolation and puriﬁcation of HBV virions from patient serum
HBV particles for infection experiments were puriﬁed from plasma, donated by
three different hepatitis B e antigen (HBeAg) positive chronic HBV carriers (for
more details see Supplementary materials and methods) using rate zonal ultra-
centrifugation through a sucrose density gradient (15 to 60% [wt/wt]) for 15 h
at 25,000 rpm as described [13]. Fractions containing high amounts of HBV
DNA were quantiﬁed by real-time PCR.HBV infection experiments
For HBV infection 24-well plates with 1  106 NTCP-HepG2 cells, PTH, or PHH
were pre-incubated for 30 min with myr-preS1 peptides or inhibitors/substrates
of NTCP in HGM at 37 C and were infected with 100 genome equivalents (GE)
of HBV per hepatocyte. After 16 h, the inoculum was collected and cells were
washed twice with HGM. Infected hepatocytes were cultured until day 11 post
infection and supernatants were harvested every 2–3 days and analysed for secre-
tion of newly synthesized Hepatitis B surface Antigen (HBsAg, PTH) or HBeAg
(HepG2). For quantitative determination of HBsAg, a mouse monoclonal antibody
mAb (C20/02) against a conformational epitopewithin the antigenic loop of HBsAg
was used in an in house ELISA system as described [13]. HBeAg was determined
using an automated microparticle enzyme immunoassay (Architect, Abbott, Wie-
sbaden, Germany). For immunostaining of newly synthesized viral proteins in
PTH, cells were plated on glass cover slips. 11 days after HBV infection cells were
washed and ﬁxed with 3% paraformaldehyde (PFA) (Sigma-Aldrich, Taufkirchen,
Germany) at 4 C. After permeabilization with 0.2% Triton X-100 in PBS for
30 min at room temperature (RT) unspeciﬁc binding epitopes were blocked by
an incubation with 10% FCS/DMEM for 1 h at RT. Expression of HBV core (HBc) par-
ticles were detected by immunostaining for 2 h at 37 C using a 1:200 dilution of a
polyclonal rabbit anti-HBcAg antiserum (Dako, Hamburg, Germany). After three
times washing with PBS, cells were incubated with anti-rabbit Alexa Fluor 594
(Invitrogen) diluted 1:200 in 0.1% BSA/DMEM for 2 h at 37 C. After extensive
washing with PBS, nuclei were stained with DAPI, again washed, mounted on glass
slides using Mowiol (Sigma-Aldrich) and visualized by confocal microscopy.Binding and colocalization analysis of viral myr-preS1 peptides
N-terminal myristoylated preS1 (amino acids 2-48) lipopeptides (further referred
to as myr-preS1 peptides) of HBV, WMHBV and WHV as well as a myr-preS1
AX594-labelled peptide (Biosynthesis, Lewisville, Texas, USA) were incubated4 vol. 61 j 867–875
JOURNAL OF HEPATOLOGY
on carrier-expressing cells at the indicated concentrations below 10 C to prevent
internalization. For interaction studies, carrier-GFP transfected HepG2 cells were
pre-incubated for 30 min in HGM with bile acids at 37 C followed by incubation
with 1 lM of the HBV myr-preS1 peptide for 30 min at <10 C. When using the
Alexa594-tagged myr-preS1 peptide, cells were washed several times with
DMEM after incubation with myr-preS1-AX594. Binding was immediately
detected by live cell confocal imaging. The myr-preS1-AX594 quantiﬁcation and
degree of colocalization was determined by using the LAS AF software (Leica,
Wetzlar, Germany). The estimated Pearson’s correlation coefﬁcient (PCC) repre-
sents the degree of overlap between ﬂuorescence signals obtained by the two
channels. The values of the PCC range from 0 (completely separated structures)
to +1 (complete colocalization).Immunoﬂuorescence of NTCP in PHH and NTCP-HepG2 cells
Primary human hepatocytes and NTCP-HepG2 cells were cultivated on glass
coverslips and ﬁxed with 3% paraformaldehyde for 45 min at 4 C at the indicated
time points post plating. For the determination of NTCP expression in NTCP-
HepG2 cells, a 1:5000 dilution of the mouse M2 mAb against the FLAG epitope
(Sigma) were used. NTCP expression in PHH was stained by using a 1:100 dilution
of a rabbit polyclonal anti-human NTCP-antibody (Prestige, Sigma Aldrich).2
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Fig. 1. HBV infection, NTCP/tNtcp expression, and Na+-dependent [3H]TC uptake of P
with the HBV, WMHBV, or WHV myr-preS1 peptides pre-incubated at increasing concent
and Na+-dependent [3H]TC uptake in PTH. (E) Time course of tNtcp mRNA and (G) NTCP p
different from day 2 pp (1way ANOVA, p <0.05).
Journal of Hepatology 201Primary antibody binding was detected by using 1:500 dilutions of Alexa488
anti-rabbit or anti-mouse secondary antibodies (Invitrogen).
Real-time PCR detection of NTCP/tNtcp expression
Total RNA of PTH and DOX induced NTCP-HepG2 cells was isolated using TriRe-
agent (Sigma) according to the manufacturers recommendation. After DNase I
digestion cDNA was synthesized using Superscript III (Invitrogen). Speciﬁc Tupaia
Ntcp and beta-actin TaqMan probes covering exon-exon boundaries were
selected and showed efﬁciencies of 99.7% and 107%, respectively. For human
NTCP detection commercially available NTCP and GAPDH TaqMan probes were
used. 50 ng cDNA per well were used for TaqMan analysis. Expression data were
calculated by the 2DDCT method.
WB detection of NTCP expression in NTCP-HepG2 cells
Proteins were isolated from NTCP-HepG2 cells with RIPA buffer (Sigma), contain-
ing protease inhibitors. 50 lg protein were separated on polyacrylamide gel (8%)
and transferred to nitrocellulose membrane. NTCP detection was performed with
mouse anti-FLAG M2 antibody (Sigma). The mouse anti-E-Cadherin antibody
(Sigma) was used for control.-1 0 1 2 3
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Na+-dependent TC uptake of hepatocytes correlates with the NTCP/
tNtcp expression and susceptibility for HBV infection
In PTH cells, TC uptake, HBV infection, and tNtcp mRNA expres-
sion were determined at different days post preparation (pp).Journal of Hepatology 201The susceptibility of PTH cells for HBV infection of puriﬁed viral
inocula from different HBV donors signiﬁcantly decreased from
maximal susceptibility at day 2 after plating below the cut-off
level for HBV infection at day 7 (Fig. 1A). HBV infection of PTH
cells was a receptor-dependent process, because it could be efﬁ-
ciently inhibited by the myr-preS1 peptides of HBV and WMHBV
with IC50 values of 1.0 nM and 1.5 nM, respectively, but not by a4 vol. 61 j 867–875 871
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WHV myr-preS1 peptide (Fig. 1B). The Na+-dependent TC uptake
in PTH cells showed a similar time-dependent decline as the HBV
susceptibility and was nearly undetectable at day 7 pp (Fig. 1C).
Overall, PTH cells showed Na+-dependent and Na+-independent
transport of TC, which both signiﬁcantly declined during cultiva-
tion (Fig. 1D). The tNtcpmRNA expression dropped already at day
3 pp to the level of day 7 pp (Fig. 1E). Similar to PTHs, Na+-depen-
dent transport of TC in PHH cells signiﬁcantly decreased within
7 days pp (Fig. 1F) and was in line with a decline of NTCP protein
expression (Fig. 1G).
Establishment of a DOX inducible NTCP-HepG2 cell line and NTCP-
speciﬁc HBV infection
By stable transfection we established a NTCP-HepG2 cell line in
which NTCP expression was under control of a CMV-Tet-on
expression system. By DOX treatment, NTCP expression could
be induced in a concentration dependent manner (Fig. 2A and
Supplementary Fig. 1A). In parallel with NTCP expression, Na+-
dependent TC transport (Fig. 2B), myr-preS1 peptide binding
(Fig. 2C and Supplementary Fig. 1B) and HBV infection (Fig. 2D)
occurred in a time-dependent and DOX-dependent manner. Fur-
thermore, we analysed, if the HBV myr-preS1 peptide not only
interacts with NTCP, but also with its closely-related carriers
ASBT and SOAT, or their functionally intact mutants ASBT/NTCP
and SOAT/NTCP (see Supplementary Fig. 2), carrying putative
HBV binding domains of NTCP [4,11,12] (Fig. 2H). NTCP-transfec-
ted HepG2 cells were labelled by the myr-preS1-AX594 peptide
(Fig. 2E and F) and support HBV infection, shown by detection
of newly produced HBeAg (Fig. 2G). At 37 C a nearly complete
co-localization of NTCP-GFP and myr-preS1-AX594 was detected
at the plasma membrane (Fig. 2E, arrow heads) and in intracellu-
lar vesicles (Fig. 2E, open arrow, NTCP containing vesicle; closed
arrow, NTCP and myr-preS1-AX594 containing vesicles), suggest-
ing internalization of the peptide-NTCP complex, whereas at 8 C
only plasma membrane derived co-localization occurred (see also
movie ‘‘Binding and uptake of HBV myr-preS1 peptide in NTCP
expressing HepG2 cells’’ in Supplementary section). In contrast,
no myr-preS1-AX594 peptide binding or HBV-infection of
transiently SOAT-, ASBT-, SOAT/NTCP-, or ASBT/NTCP-GFP or
-FLAG transfected HepG2, respectively, cells could be observed
(Fig. 2F and G). The NTCP-directed HBV infection of HepG2 cells
was completely abolished by the HBV myr-preS1 peptide
(Fig. 2G).
Inhibition of NTCP-mediated TC transport by myr-preS1 peptides
Binding of the HBV myr-preS1 peptide to NTCP suggested that
these peptides may interfere with the bile acid transport function
of NTCP. Therefore, we performed transport experiments with TC
on PTH, PHH, NTCP-HepG2 cells, and NTCP-HEK293 cells as well
as for control on ASBT-HEK293 and with DHEAS on SOAT-
HEK293 cells in the presence of the respectivemyr-preS1 peptides
(Fig. 3A). HBV myr-preS1 peptides signiﬁcantly inhibited the TC
uptake of PTH (Fig. 3B) and PHH cells (Fig. 3C) down to 25% of
the control uptake with IC50 values of 1.9 nM and 9.7 nM,Fig. 4. Bile acids and ezetimibe block HBV infection. (A) Chemical structures of inhibito
was inhibited by the indicated compounds at the given concentrations. HBV infection
ezetimibe (EZ) at the indicated inhibitory concentrations. (H) Inhibition of HBV myr-pre
Journal of Hepatology 201respectively. Furthermore, the TC uptake of NTCP-HepG2
(Fig. 3D) and NTCP-HEK293 cells (Fig. 3E) was completely blocked
by the HBV myr-preS1 peptides with IC50 values of 68 nM and
190 nM, respectively. In NTCP-HepG2 cells, IC50 values for myr-
preS1 mediated transport inhibition clearly correlated with the
overall NTCP transport rate (Fig. 3F). The transport of ASBT and
SOAT was not inﬂuenced by myr-preS1 peptides (Fig. 3A).
Competition between HBV attachment and NTCP ligand binding
To analyse if ligands of NTCP may interfere with the attachment
and infectivity of HBV, several taurine and glycine conjugates of
cholic acid (TC and GC) and ursodeoxycholic acid (UDC, TUDC,
GUDC) as well as dehydrocholic acid (DHC), and ezetimibe (EZ)
(Fig. 4A) were tested for their inhibitory potential on the TC
uptake by PTH (Fig. 4B) and NTCP-HepG2 cells (Fig. 4D). Inhibi-
tion of TC uptake in PHH was only tested with EZ (Fig. 4C). All
three cell systems were pre-incubated with up to 100 lM of
the respective compounds for 30 min before the TC uptake was
analysed over 10 min in the presence of inhibitors. In PTH,
PHH, and NTCP-HepG2 cells, all tested compounds except of
DHC strongly inhibited the TC uptake. After 30 min pre-
incubation and subsequent wash-out, TC, GC, UDC, TUDC, and
EZ (at 25 lM) did not affect the TC uptake over 10 min, whereas
GUDC and EZ (at 100 lM) reduced the NTCP activity in NTCP-
HepG2 cells by >50% (Fig. 4D, right panel). As a control, we used
taurolithocholic acid (TLC) that has been reported to result in a
rapid loss of NTCP from the plasma membrane during pre-
incubation of the cells [13,16]. In parallel we investigated, if these
inhibitory effects interfere with the HBV susceptibility. Therefore,
PTH (Fig. 4E), PHH (Fig. 4F) and NTCP-HepG2 cells (Fig. 4G) were
incubated with increasing concentrations of the indicated com-
pounds for 30 min, before HBV infection. Similar to the transport
inhibition, all compounds (except of DHC), showed a concentra-
tion-dependent inhibition on the HBV infection. No cytotoxicity
was observed at given concentrations of the inhibitory com-
pounds (Supplementary Fig. 3). Apart from HBV infection, we also
analysed the effect of bile acids and EZ on the myr-preS1 peptide
binding to NTCP (Fig. 4H, Supplementary Fig. 4). Similar to HBV
infection (Fig. 4G), inhibition of HBV myr-preS1-AX594 peptide
binding was particularly effective with TUDC (Fig. 4H). EZ also
showed strong inhibitory effects on HBV myr-preS1-AX594 pep-
tide binding and HBV infection (Fig. 4E–H) at least at 100 lM.Discussion
Recently, Yan et al. were the ﬁrst to demonstrate that NTCP rep-
resents a functional high-speciﬁc receptor for HBV infection [4].
The data of the present study fully support this ﬁnding and show
that myr-preS1 peptide binding and infectivity of HBV in PTH,
PHH as well as in HepG2 cells clearly depend on functional
NTCP/tNtcp expression. In PTH and PHH cells, HBV susceptibility
and Na+-dependent bile acid transport simultaneously declined
during few days pp and were nearly undetectable at day 7 pp.
This decline was ﬁrst observed at the mRNA level and was fol-ry compounds. Transport of [3H]TC in PTH (B), PHH (C), and NTCP-HepG2 cells (D)
of PTH (E), PHH (F), and NTCP-HepG2 cells (G) was inhibited by bile acids and
S1-AX594 peptide binding (red) to NTCP-HepG2 cells by bile acids and EZ.
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lowed by the functional protein expression (Fig. 1). Similar
results were reported in freshly isolated rat hepatocytes, in which
a time-dependent decline in the Na+-dependent TC uptake was
associated with down-regulation of the rat Ntcp mRNA [17].
Although in primary hepatocyte cultures nearly every cell
expresses NTCP shortly after plating, the number of HBV-infected
cells in those cultures is usually around 20–25% as seen by us and
others [4]. A similar magnitude of infection can also be seen with
our NTCP-HepG2 cell line and was also reported for NTCP-
transfected HepG2 and HuH7 cell lines [4]. The reason for this
phenomenon is still unclear and might be due to restrictions of
a still unknown HBV post-entry step.
The establishment of a HepG2 cell line with inducible NTCP-
expression allowed us to analyse NTCP-related HBV susceptibil-
ity, myr-preS1 peptide binding and bile acid uptake more in
detail (Fig. 2). Differential induction of NTCP-expression by
dose-dependent DOX-treatment correlated with NTCP mRNA
and protein expression. Kinetics of NTCP-induction, TC uptake
and myr-preS1 peptide binding reached its maximum after 48 h
DOX treatment. After DOX withdrawal, NTCP expression, TC
uptake, myr-preS1-peptide binding and HBV infection in NTCP-
HepG2 cells followed similar kinetics as in primary hepatocytes.
Thus, it can be concluded that the decline of HBV susceptibility
and Na+-dependent bile acid transport observed in PTH and
PHH cells within few days pp clearly depends on functional NTCP
expression. At least in PTH also the Na+-independent part of the
total TC uptake declined over time, which was most likely
mediated by hepatic carriers of the organic anion transporting
polypeptide (OATP) family [6,17]. Our NTCP-HepG2 cell line
now allows to balance the NTCP expression at the physiological
level, giving advantage over other maximally over-expressing
systems [4,12,13,18,19].
Apart from NTCP, the SLC10 carrier family contains two fur-
ther carriers, ASBT and SOAT, with high sequence and structural
homology to NTCP [5]. However, whereas the ASBT and SOAT
transport functions are quite speciﬁc for bile acids and sulfated
steroids, respectively, NTCP has a broader substrate pattern
including both kinds of substrates [5–8]. Therefore, we were
interested if HBV may also bind to ASBT or SOAT via its myr-
preS1 peptide. But we clearly show that both carriers do neither
bind the myr-preS1 peptide nor support HBV infection. Even inte-
grating the two putative HBV myr-preS1 binding domains of
NTCP [4,11,12] into the respective sites of ASBT and SOAT did
not support myr-preS1 binding or HBV infection (Fig. 2E–G).
These data underline the liver-speciﬁc HBV susceptibility via
NTCP binding, whereas the homologous carriers ASBT and SOAT,
mainly expressed in gut and testis [5,8], respectively, are not tar-
geted by HBV.
A further intriguing ﬁnding of the present study is that the
myr-preS1 peptide-dependent attachment of HBV to NTCP and
the bile acid transport function of NTCP clearly interfere with
each other: The myr-preS1 peptides of HBV and WMHBV (but
not of WHV) signiﬁcantly inhibited the TC transport in PTH and
PHH, and completely blocked the TC uptake in NTCP-HepG2
and NTCP-HEK293 cells (Fig. 3); vice versa, certain bile acids
clearly inhibited HBV infection of PTH, PHH, and NTCP-HepG2
cells and dramatically blocked the myr-preS1-AX594 peptide
binding to NTCP (Fig. 4E–H). However, it has to be noted that a
30 min incubation of NTCP-HepG2 cells with GUDC at 100 lM
and 400 lM as well as EZ at 100 lM signiﬁcantly reduced the
NTCP transport activity, even after a 10 min wash-out phase874 Journal of Hepatology 201(Fig. 3D). This could be explained by NTCP retrieval from the
plasma membrane, which was previously reported for taurolitho-
cholic acid (TLC) and taurochenodeoxycholic acid [13,16]. Never-
theless it can be concluded that bile acid substrate binding and
myr-preS1 peptide binding to NTCP directly interfere with each
other, also supporting very recent ﬁndings from other groups
[12,13]. Yan et al. also used PTH to show myr-preS1 peptide-
induced inhibition of the Na+-dependent [3H]TC transport. How-
ever, in contrast to the present study, Yan et al. found stronger a
effect of TUDC on HBV infection in PTH [13].
In the present study we used UDC and TUDC as potential myr-
preS1 peptide binding inhibitor (Fig. 4H). UDC is an approved
drug for a variety of chronic liver diseases such as dissolution
of cholesterol gallstones and the improvement and delay of pro-
gression of primary biliary cirrhosis (PBC), and lacks any cytotox-
icity up to concentrations of 500 lM [20]. Standard treatment
doses of UDC are at 12–15 mg/kg body weight and make UDC
and UDC-conjugates to the predominant bile acids within the
endogenous bile acid pool. Under treatment of PBC patients,
UDC and UDC-conjugates reach plasma concentrations up to
17 lM [21]. However, this concentration seems to be too low
for >50% inhibition of HBV infection at least in our in vitro assay
(Fig. 4E–G). Clinical studies about the inﬂuence of bile acids on
the course of hepatitis B came to inconclusive results [22], and
currently there is no clear evidence for a protective role of UDC
treatment in hepatitis B under standard treatment conditions.
Apart from bile acids, in vivo experiments already conﬁrmed
that hepadnaviral myr-preS1 peptides are potent inhibitors of
HBV infection, even at low nanomolar concentrations, and the
myr-preS1 peptide-derived drug Myrcludex B is currently under
development as an elegant and promising approach for interven-
tion of HBV infection [23]. However, it cannot be excluded that
therapeutically used myr-preS1 peptide derivatives may hamper
the enterohepatic circulation of bile acids by blocking the NTCP-
mediated bile acid transport into hepatocytes. While there might
be no serious side effects during short-term treatment, e.g. for
HBV post exposure prophylaxis, effects on the bile acid homeo-
stasis should be carefully monitored under long term treatment,
e.g. in chronically HBV-infected patients.
In subsequent studies it will be interesting to investigate if
already labelled drugs which have been shown to inhibit the
transport function of NTCP, in the same way and with compara-
ble inhibition kinetics could also block myr-preS1 peptide
binding and HBV infection of NTCP-expressing liver cells. These
drugs include cyclosporine A, propranolol, bumetanide, simvasta-
tin, irbesartan, doxazosin, and many others [24,25]. Very recent
studies already demonstrated that cyclosporine A efﬁciently can
block myr-preS1 peptide binding to NTCP and HBV infection of
HBV susceptible cells [18,19]. In the present study we closer
analysed the lipid lowering drug ezetimibe, which is a speciﬁc
inhibitor of the intestinal Niemann-Pick C1-like cholesterol trans-
porter and has shown before a signiﬁcant inhibition of NTCP with
a Ki of 25 lM [25]. In our study, ezetimibe signiﬁcantly inhibited
the TC transport in PTH, PHH, and NTCP-HepG2 cells, and also
inhibited the HBV infection of these cells (Fig. 4). However, eze-
timibe at a concentration of 100 lM signiﬁcantly reduced the
TC transport activity of NTCP after 30 min pre-incubation and
10 min wash-out (Fig. 4D). Therefore, the inhibition of myr-preS1
peptide binding and HBV infection by 100 lM ezetimibe might be
a mixed effect of NTCP inhibition and internalization. Further-
more, as ezetimibe plasma concentrations under standard4 vol. 61 j 867–875
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treatment are far below these values effective for HBV inhibition,
i.e., in the range of about 15 nM [26], ezetimibe might not be the
appropriate drug for treatment of chronic HepB patients. Never-
theless, our data indicate that HBV infection indeed may be treat-
able with a chemical compound of low molecular weight.
In conclusion: Myr-preS1 dependent viral binding to NTCP,
necessary for productive HBV infection, interacts with the phys-
iological bile acid transport function of NTCP. Therefore, HBV
infection via NTCP may be lockable by NTCP substrates and
NTCP-inhibiting drugs. This opens a completely new way for an
efﬁcient management of HBV infection by the use of NTCP-
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